UK Statutory Scheme Rebate Rise Could Cause Product Shortages & Launch Delays

The pharmaceutical industry is calling on the government to take steps to restore the UK as a location for life sciences investment and recognize the role of competition in the branded generics market, but it will need strong evidence to make the most convincing case.

Close-up shot of pills with stamped pound sterling GBP symbol on them.
The statutory scheme is one way to govern drug prices in the UK • Source: Shutterstock

The latest proposed hike in rebates due from companies under the UK’s statutory scheme to control the costs of branded medicines is predicted to add further pressure on medicine supply and could even delay or even stop some product launches in the UK, industry sources have warned. 

The increase in the rebate under the statutory scheme is driven by a need to align with the higher rebate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography